openPR Logo
Press release

Adrenocortical Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

04-03-2019 02:49 PM CET | Health & Medicine

Press release from: Pharma Proff

Adrenocortical Carcinoma Therapeutics - Pipeline Analysis

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney.

Download the sample report @ https://www.pharmaproff.com/request-sample/1109

Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla). Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome.

Get the detailed analysis @ https://www.pharmaproff.com/report/adrenocortical-carcinoma-therapeutics-pipeline-analysis

Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1109

Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Adrenocortical Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results here

News-ID: 1686058 • Views:

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developments
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant Growth due to Increasing Strategic Developments in the Coming Years | Top Players are Orphazyme A/S, IntraBio Ltd., CTD Holdings, Inc., Mallinckrodt Pharmaceuticals, SOM Biotec
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Adrenocortical

Adrenocortical Hormones API Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Drugs Market Overview: Growth, Share, Value, Size, and …
The global Adrenocortical Carcinoma Drugs market is projected to reach approximately USD 0.85 billion by 2033, growing at a compound annual growth rate (CAGR) of around 7.2% from 2025 to 2033. Adrenocortical Carcinoma Drugs Market Overview The global Adrenocortical Carcinoma (ACC) drugs market is experiencing growth, driven by the increasing incidence of this rare endocrine malignancy and advancements in therapeutic approaches. ACC is characterized by aggressive tumor behavior and limited treatment options,
Adrenocortical Hormones API Market Survey Detailed Analysis and Forecast 2024-20 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs, For External Use Drugs, Inhalation Drugs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Adrenocortical Hormones API Market is valued at US$ 2.24 Billion
Adrenocortical Carcinoma Treatment: Challenges, Advances, and Market Dynamics
Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer originating in the adrenal cortex, the outer layer of the adrenal glands. These glands, located above the kidneys, are responsible for producing hormones that regulate a variety of bodily functions, such as metabolism, blood pressure, and immune response. ACC is often diagnosed at an advanced stage due to its asymptomatic early course, and treatment options are limited. In this
Adrenocortical Hormones API Market Research Explores Revenue Share Study Analysi …
Adrenocortical Hormones API Market is valued at US$ 2.24 Billion in 2023, and it is expected to reach US$ 3.55 Billion by 2031, with a CAGR of 6.04 % during the forecast period of 2024-2031. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adrenocortical Hormones API Market - (By Type (Dexamethasone Series, Betamethasone Series, Hydrocortisone Series & Others), By Application (Injectable Drugs, Oral Drugs,
Adrenocortical Hormones API Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Adrenocortical Hormones API market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Adrenocortical Hormones APImarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Adrenocortical Hormones APImarket, market definition, overview, industry opportunities